We demonstrate that GenIE can assay intronic transcriptional enhancers and splicing regulatory elements in hiPSCs, apply it to screen variants involved in Alzheimer's disease (AD) at the clusterin (CLU) locus, and perform saturation editing across a splice site to quantify the effects of point mutations on splicing. Here, CLU is linked to Alzheimer disease.